Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05636150
Other study ID # 2021-013-CH07 IIT-EC
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 30, 2022
Est. completion date August 30, 2024

Study information

Verified date December 2022
Source Peking Union Medical College Hospital
Contact Zhao Lin, MD
Phone 69158753
Email wz20010727@aliyun.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Investigators conduct the clinical trial to further explore the efficacy and safety of Fruquintinib combined with S-1 in treating recurrent or metastatic esophageal squamous cell carcinoma after the failure of conventional treatments.


Description:

Esophageal cancer is one of the most common malignant tumor and esophageal squamous cell carcinoma is the main pathological type of esophageal carcinoma in China. Among patients with advanced or metastatic esophageal squamous cell carcinoma, the addition of immunotherapy to chemotherapy, compared with placebo and chemotherapy, significantly improved overall survival and progression-free survival.Treatment of recurrent or metastatic esophageal squamous cell carcinoma is usually poor. New treatments were needed. Fruquintinib is an orally antiangiogenic agents, which target VEGFR1/2/3. A combination of Fruquintinib and s-1 for advanced or metastatic esophageal squamous cell carcinoma could be a novel therapy. Therefore, investigators initialize this phase II study to explore the safety of fruquintinib and S-1 combination treatment in ESCC patients with after failure in 1st-line immunotherapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date August 30, 2024
Est. primary completion date March 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or female patients, age:=18 years old - Imageology diagnosed with refractory or metastatic esophageal squamous cell carcinoma - Disease progression after the last dose of the first-line therapy (with immunotherapy, without fluoropyrimidine) - At least one measurable lesion (RECIST1.1) - Good performance status Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 to 2 - Life expectancy of more than 12 weeks - The test value for bone marrow, liver and renal function evaluation within 7 days prior to first dosing should meet requirements - Negative of blood pregnancy test within 7 days prior to first dosing for fertile female patients. Fertile female and male patients agree to use effective contraceptive methods during the study and within 6 months post to the last dose, such as double barrier contraception, condoms, oral or injection contraceptives, intrauterine devices, abstinence, etc. All female patients will be considered fertile unless the female patient has natural menopause or has undergone artificial menopause or sterilization (hysterectomy, bilateral appendage resection); - Signed informed consent Exclusion Criteria: - Absolute neutrophil count (ANC) <1.5×109/L, platelet count <75×109/L, and hemoglobin <9g/dL - Serum total bilirubin >1.5× the upper limit of normal (ULN) - Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) >2.5×ULN - Creatinine > 1.5 × ULN or creatinine clearance <50 mL/min - Activated partial thromboplastin time (APTT)> 1.5 × ULN - The investigators determined clinically significant severe electrolyte abnormalities. - Proteinuria = 2+ (1.0g/24hr) - Drug uncontrollable hypertension, defined as systolic blood pressure = 140 mmHg and / or diastolic blood pressure = 90 mmHg - The patients have active ulcer of stomach and duodenum, ulcerative colitis and other digestive tract diseases or unresectable tumors with active bleeding, or other conditions that may cause gastrointestinal bleeding and perforation, as judged by investigators; or the existence of gastrointestinal perforation or gastrointestinal fistula uncured post to previous surgical treatment - Patients with evidence or history of propensity to hemorrhage within 2 months prior to first dosing, regardless of severity(such as melena, hematemesis, hemoptysis, bloody stools) - Arterial thrombosis or deep venous thrombosis within 6 months prior to first dosing, or thromboembolic events - Cardiovascular diseases of significant clinical significance, including, but not limited to acute myocardial infarction, severe/unstable angina pectoris or coronary artery bypass grafting within 6 months prior to first dosing, congestive heart failure with New York Heart Association (NYHA) grade = 2; Left ventricular ejection fraction (LVEF) < 50% - Uncontrolled malignant pleural effusion, ascites or pericardial effusion - Previous treatment with anti-vascular endothelial growth factor receptor (VEGFR) inhibitors - A history of other malignancies within 5 years prior to inclusion, except for cervical carcinoma in situ, basal or squamous cell skin cancer - Distal metastasis to brain - History of clinically significant hepatic disease, including, but not limited to, known hepatitis B virus (HBV) infection with HBV DNA positive (copies =1×104/ml); known hepatitis C virus infection with HCV RNA positive - Women who are pregnant or lactating - Patients considered unsuitable for inclusion in this study by the investigator - Patients considered a serious mental or mental abnormality

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fruquintinib in Combination with S-1
Cohort A: Fruquintinib 3 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w. Cohort B: Fruquintinib 4 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w. Cohort C: Fruquintinib 5 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w. Patients will be treated until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.

Locations

Country Name City State
China Peking Union Medical College Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression free survival (PFS) PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. From date of first dose of study drug until disease progression, withdrawal of consent, death (up to approximately 1 year)
Secondary Overall survival (OS) Baseline to measured date of death from any cause (up to approximately 1 year)
Secondary Objective response rate (ORR) Tumor assessment will be performed using radiography method every 6 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1 from treatment up to progressive disease or EOT due to any cause up to 1 year
Secondary Disease control rate (DCR) Tumor assessment will be performed using radiography method every 6 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1 from treatment up to progressive disease or EOT due to any cause up to 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT06056336 - Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma Phase 2
Suspended NCT04084158 - A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Not yet recruiting NCT05561699 - Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer N/A
Active, not recruiting NCT04543617 - A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy Phase 3
Recruiting NCT06190782 - Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor Phase 3
Completed NCT05557955 - Identification of Breath Biomarkers in Esophageal Cancer
Recruiting NCT04045496 - A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Not yet recruiting NCT03766178 - Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT02913066 - S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma Phase 2
Completed NCT02399306 - Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma Phase 3
Completed NCT01605305 - Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer Phase 2
Not yet recruiting NCT05552651 - Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT05520619 - Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) Phase 2
Terminated NCT03251417 - Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT05990231 - Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy Phase 2
Recruiting NCT04644250 - Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma Phase 2
Completed NCT02916511 - Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma Phase 2
Terminated NCT04032704 - A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Phase 2